{"product_id":"70-years-of-weight-loss-surgery-research-what-we-know-what-we-dont-and-why-that-matters-for-patients","title":"70 Years of Weight-Loss Surgery Research: What We Know, What We Don't, and Why That Matters for Patients","description":"\u003cp\u003eResearchers at Paris' European Hospital Georges Pompidou conducted the first comprehensive mapping of all randomized controlled trials (RCTs) in bariatric (weight-loss) surgery, spanning nearly 70 years of research from the first trial in 1977 through 2020. After screening more than 53,000 scientific references, they identified 114 high-quality trials and found significant research waste: most studies were small, short-term, and repeated the same research questions, while crucial areas like mental health, nutritional deficiencies, and long-term outcomes received minimal attention. The study, published in \u003cem\u003eObesity Reviews\u003c\/em\u003e, calls for a dramatic rethinking of how weight-loss surgery research is conducted, including larger international trials, longer follow-up periods, and a standardized set of outcomes that reflect what patients truly care about.\u003c\/p\u003e\n\n\u003ch1\u003e70 Years of Weight-Loss Surgery Research: What We Know, What We Don't, and Why That Matters for Patients\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eWhy This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow the Research Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#findings\"\u003eKey Findings: The State of Weight-Loss Surgery Research\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#gaps\"\u003eCritical Research Gaps Identified\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for the Future\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eA review of 114 randomized trials from 1977–2020 found most bariatric surgery research is small, short-term, and repeats similar questions.\u003c\/li\u003e\n\u003cli\u003eWeight loss was studied in 87% of trials, but quality of life in only one-third and mental health in only 5%.\u003c\/li\u003e\n\u003cli\u003eOnly 15% of trials were multicenter and just 3.5% were international; most studies followed patients for only 1–2 years.\u003c\/li\u003e\n\u003cli\u003eRoux-en-Y gastric bypass was studied in most trials, though sleeve gastrectomy is now the most commonly performed procedure.\u003c\/li\u003e\n\u003cli\u003eExperts recommend standardized outcomes, longer follow-up, and international research collaborations to better answer what patients truly care about.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eWhy This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eOver the past 50 years, obesity has grown worldwide to what experts describe as \"pandemic proportions.\" This is not just a cosmetic issue — it's a major health crisis linked to diabetes, heart disease, and many other serious conditions.\u003c\/p\u003e\n\n\u003cp\u003eWeight-loss surgery, formally known as \u003cstrong\u003ebariatric surgery (BS)\u003c\/strong\u003e, has been practiced since the 1950s and has become a common treatment for severe obesity. Today, it is considered the most successful therapeutic option for severe obesity, offering long-term positive effects that go far beyond simply shedding pounds.\u003c\/p\u003e\n\n\u003cp\u003eBeyond weight reduction, bariatric surgery provides significant benefits for blood glucose control and diabetes risk. This has led to the rise of what doctors call \u003cstrong\u003e\"metabolic surgery\"\u003c\/strong\u003e — surgery performed specifically to treat diabetes and metabolic disorders, even in patients who may not meet traditional weight-based criteria for surgery.\u003c\/p\u003e\n\n\u003cp\u003eA January 2021 survey by the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) reported a total of \u003cstrong\u003e604,223 yearly primary bariatric procedures worldwide\u003c\/strong\u003e, with sleeve gastrectomy remaining the most commonly performed procedure. Yet despite this massive volume of surgery, no one had ever systematically mapped the randomized controlled trials — the gold standard of medical evidence — in this field.\u003c\/p\u003e\n\n\u003cp\u003eThis matters because understanding what research has been done, what questions remain unanswered, and where efforts are being wasted is essential for improving patient care. This study set out to fill that gap by mapping every RCT conducted in bariatric surgery since the very first one was published in 1977.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow the Research Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThe researchers performed a systematic review — a rigorous, structured method of searching and analyzing all available scientific literature on a topic. Their goal was twofold: to map all existing randomized controlled trials in bariatric surgery and to identify where research efforts have been duplicated or neglected.\u003c\/p\u003e\n\n\u003cp\u003eHere's how they did it, step by step:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDatabase searches:\u003c\/strong\u003e From January 2020 to December 2020, they systematically searched two major medical databases — Embase and PubMed — covering research from 1977 (when the first bariatric surgery RCT was published) through 2020.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSearch criteria:\u003c\/strong\u003e They used 2015 Medical Subject Headings (MeSH) terms from the US National Library of Medicine, a standardized vocabulary used to index medical research.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStudy selection:\u003c\/strong\u003e They included trials that compared two bariatric surgery techniques against each other, or bariatric surgery against a medical (non-surgical) treatment, in adult patients. There was no restriction on what outcomes the trials measured.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIndependent review:\u003c\/strong\u003e Two reviewers independently checked each study against the eligibility criteria. When they disagreed, a third reviewer helped reach a consensus.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eData collection:\u003c\/strong\u003e For each trial, they recorded the comparators (what was being compared), interventions, location, journal, year of publication, number of patients, follow-up times, and patient characteristics including average age, weight, body mass index (BMI), percentage of women, percentage with diabetes, and glycated hemoglobin (HbA1c) levels (a measure of blood sugar control over time).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOutcome classification:\u003c\/strong\u003e They categorized all outcomes into several groups including efficacy, surgery and perioperative period (around the time of surgery), mortality, complications, and tolerance.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe initial electronic search yielded an enormous pool of \u003cstrong\u003e53,258 references\u003c\/strong\u003e — 17,655 from PubMed and 35,603 from Embase. After removing 6,682 duplicates, they excluded 45,286 studies based on their titles and another 897 based on their abstracts. Of the 363 studies selected for full-text evaluation, \u003cstrong\u003e114 randomized controlled trials\u003c\/strong\u003e met all criteria and were included in the final analysis.\u003c\/p\u003e\n\n\u003ch2 id=\"findings\"\u003eKey Findings: The State of Weight-Loss Surgery Research\u003c\/h2\u003e\n\n\u003cp\u003eThe findings paint a revealing picture of seven decades of research — some encouraging, some concerning, and some frankly wasteful.\u003c\/p\u003e\n\n\u003ch3\u003eWhich Procedures Were Studied?\u003c\/h3\u003e\n\n\u003cp\u003eThe majority of trials — \u003cstrong\u003e73.7%\u003c\/strong\u003e — were based on comparison with \u003cstrong\u003eRoux-en-Y gastric bypass (RYGB)\u003c\/strong\u003e, a procedure that creates a small stomach pouch and reroutes the small intestine. This is notable because while RYGB has long been considered the \"gold standard\" of bariatric surgery, it is no longer the most commonly performed procedure worldwide.\u003c\/p\u003e\n\n\u003cp\u003eIn fact, \u003cstrong\u003esleeve gastrectomy (SG)\u003c\/strong\u003e — a procedure that removes about 80% of the stomach to create a sleeve-shaped pouch — is now the most commonly performed bariatric procedure according to the latest data, yet it has been far less studied. This gap between what surgeons actually do and what researchers actually study is a significant finding of this review.\u003c\/p\u003e\n\n\u003ch3\u003eWhen and Where Were the Trials Conducted?\u003c\/h3\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e74.6%\u003c\/strong\u003e of trials were conducted between 2010 and 2020, showing that this field of research is relatively young and expanding rapidly\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e44%\u003c\/strong\u003e of trials were conducted in Europe, making it the most active region for bariatric surgery research\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e15%\u003c\/strong\u003e of trials were multicenter (involving multiple hospitals or clinics)\u003c\/li\u003e\n  \u003cli\u003eOnly \u003cstrong\u003e3.5%\u003c\/strong\u003e of trials were international — a strikingly low number that suggests a \"compartmentalization\" of research along national lines\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e88.6%\u003c\/strong\u003e of trials involved current bariatric surgery procedures still in use today\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e71.1%\u003c\/strong\u003e of trials used a surgical comparator (another surgery), rather than comparing surgery to medical treatment\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003ePatient Numbers and Follow-Up: A Major Concern\u003c\/h3\u003e\n\n\u003cp\u003eThe median number of patients enrolled in each trial was just \u003cstrong\u003e61 patients\u003c\/strong\u003e (interquartile range: 47.3 to 100). This means half of all trials enrolled fewer than 61 people. While this sample size is comparable to other fields of surgical research, it is small compared with medical treatment research.\u003c\/p\u003e\n\n\u003cp\u003eFollow-up times were equally concerning. Most studies followed patients for only 1 or 2 years:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e36%\u003c\/strong\u003e of trials had follow-up of 1 year or less\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e22.8%\u003c\/strong\u003e had follow-up between 1 and 2 years\u003c\/li\u003e\n  \u003cli\u003eOnly \u003cstrong\u003e16%\u003c\/strong\u003e had follow-up between 2 and 3 years\u003c\/li\u003e\n  \u003cli\u003eJust \u003cstrong\u003e5 studies (4.4%)\u003c\/strong\u003e had follow-up between 3 and 4 years\u003c\/li\u003e\n  \u003cli\u003eOnly \u003cstrong\u003e24 studies (21.1%)\u003c\/strong\u003e had follow-up beyond 4 years\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis is particularly problematic because obesity is a chronic disease that lasts a lifetime. A 1- or 2-year follow-up is far too short to know whether the benefits of surgery — and its potential complications — hold up over the long term.\u003c\/p\u003e\n\n\u003ch3\u003eWho Was Studied?\u003c\/h3\u003e\n\n\u003cp\u003eThe patient populations in these trials were fairly consistent across studies. The median proportion of women was \u003cstrong\u003e69.8%\u003c\/strong\u003e (interquartile range: 60–77.8%), reflecting the fact that women are more likely than men to seek bariatric surgery. The median age of participants was \u003cstrong\u003e44.4 years\u003c\/strong\u003e (IQR: 37.6–49), and the median BMI was \u003cstrong\u003e42.4 kg\/m²\u003c\/strong\u003e (IQR: 36.1–45.3), which falls squarely in the severe obesity range.\u003c\/p\u003e\n\n\u003cp\u003eNotably, \u003cstrong\u003e39.5%\u003c\/strong\u003e of the trials were performed specifically in patients with diabetes. In those diabetes-focused studies, a median of \u003cstrong\u003e69.8%\u003c\/strong\u003e of participants had diabetes. Interestingly, the researchers point out that the prevalence of diabetes in these trial populations exceeds 70% in some cases — far higher than the actual prevalence of diabetes among bariatric surgery patients in real-world clinical practice, which they note is lower. This disconnect raises questions about whether trial results truly apply to the broader population of patients seeking weight-loss surgery.\u003c\/p\u003e\n\n\u003cp\u003eWhen it came to publication impact, only \u003cstrong\u003e22.8%\u003c\/strong\u003e of trials were published in journals with an impact factor above 10. (Impact factor is a measure of how often articles in a journal are cited by other researchers; higher numbers generally indicate more influential journals.)\u003c\/p\u003e\n\n\u003ch2 id=\"gaps\"\u003eCritical Research Gaps Identified\u003c\/h2\u003e\n\n\u003cp\u003ePerhaps the most important contribution of this study is its detailed analysis of what outcomes researchers chose to measure — and, crucially, what they chose \u003cem\u003enot\u003c\/em\u003e to measure.\u003c\/p\u003e\n\n\u003ch3\u003eThe Most Studied Outcomes\u003c\/h3\u003e\n\n\u003cp\u003eThe researchers categorized all outcomes into several groups. Weight loss dominated the field:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWeight loss\u003c\/strong\u003e was studied in \u003cstrong\u003e87%\u003c\/strong\u003e of RCTs — by far the most common outcome\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eObesity-related diseases\u003c\/strong\u003e (such as diabetes, hypertension, and high cholesterol) were studied in \u003cstrong\u003e73%\u003c\/strong\u003e of RCTs\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedical complications\u003c\/strong\u003e were studied in \u003cstrong\u003e54%\u003c\/strong\u003e of RCTs\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSurgical complications\u003c\/strong\u003e were studied in \u003cstrong\u003e47%\u003c\/strong\u003e of RCTs\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePerioperative time\u003c\/strong\u003e (time around surgery) was measured in \u003cstrong\u003e39%\u003c\/strong\u003e of RCTs\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMortality\u003c\/strong\u003e (death rates) was studied in \u003cstrong\u003e33%\u003c\/strong\u003e of RCTs\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIntermediate metabolic markers\u003c\/strong\u003e (measures like blood sugar, insulin resistance, inflammation, gut hormones) were studied in \u003cstrong\u003e28%\u003c\/strong\u003e of RCTs\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTolerance\u003c\/strong\u003e (how well patients tolerated the procedure) was studied in \u003cstrong\u003e25%\u003c\/strong\u003e of RCTs\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEating behavior\u003c\/strong\u003e was studied in just \u003cstrong\u003e9%\u003c\/strong\u003e of RCTs\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHealth costs\u003c\/strong\u003e were studied in just \u003cstrong\u003e9%\u003c\/strong\u003e of RCTs\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEnergy expenditure\u003c\/strong\u003e (calories burned) was studied in only \u003cstrong\u003e4%\u003c\/strong\u003e of RCTs\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eStriking Under-Investigated Areas\u003c\/h3\u003e\n\n\u003cp\u003eSome of the most important — and most neglected — areas included:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNutritional deficiencies:\u003c\/strong\u003e Studied in only \u003cstrong\u003e20%\u003c\/strong\u003e of RCTs, despite the fact that bariatric surgery can dramatically affect the body's ability to absorb essential vitamins and minerals\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBody composition:\u003c\/strong\u003e Studied in only \u003cstrong\u003e18%\u003c\/strong\u003e of RCTs — a concern because loss of lean muscle mass after surgery can be pathological (disease-related)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMental health:\u003c\/strong\u003e Studied in a mere \u003cstrong\u003e5%\u003c\/strong\u003e of RCTs, despite the well-documented appearance of depressive syndromes and addiction issues in some patients after bariatric surgery\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eQuality of life:\u003c\/strong\u003e Studied in only one-third of RCTs — particularly striking since the researchers note that quality of life is likely \"the most relevant\" question to patients themselves\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe researchers also noted that while \u003cstrong\u003ediabetes resolution\u003c\/strong\u003e (curing or improving diabetes) was one of the most studied outcomes, hypertension (high blood pressure) resolution, body composition changes, nutritional deficiency risk, and mental health were all left \"under-investigated.\"\u003c\/p\u003e\n\n\u003ch3\u003eRepeated Questions, Wasted Resources\u003c\/h3\u003e\n\n\u003cp\u003eThe study's most damning finding is the degree of \u003cstrong\u003eresearch waste\u003c\/strong\u003e. The researchers documented \"repetition of small sample size studies, with short follow-up and the same outcomes (weight loss and diabetes resolution).\" In other words, researchers have repeatedly asked the same questions in small, underpowered studies rather than building a cumulative, coordinated body of evidence.\u003c\/p\u003e\n\n\u003cp\u003eThe evolution of outcomes over time (shown in the study's Figure 5) demonstrates that the pattern of outcomes studied has been \"mainly influenced by the last 10 years\" — meaning the recent explosion of research has largely replicated existing work rather than exploring new frontiers.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eFor patients considering or undergoing bariatric surgery, these findings carry several important implications.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFirst, the evidence base is narrower than it appears.\u003c\/strong\u003e While hundreds of studies exist, they cluster around a few procedures (particularly RYGB) and a few outcomes (particularly weight loss and diabetes). The evidence base for sleeve gastrectomy — the most commonly performed procedure today — lags behind, which the researchers describe as a \"delay or a gap in research concerning SG.\"\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSecond, the long-term picture is unclear.\u003c\/strong\u003e Since most trials follow patients for only 1 to 2 years, little is known from controlled trials about what happens 5, 10, or 20 years after surgery. For a chronic disease like obesity, this is a fundamental problem. The researchers note that long-term outcomes such as life expectancy are better addressed by other types of studies, including cohort studies and national administrative databases, which have already provided valuable long-term data.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThird, what matters most to patients may be the least studied.\u003c\/strong\u003e The researchers write: \"Assuming that quality of life after BS is the most relevant to patients, we consider that the main question that patients ask themselves when they turn to this surgery has been insufficiently studied.\" If you are considering bariatric surgery, you likely have questions about what daily life will be like afterward — how your eating habits will change, how your mental health might be affected, whether you'll develop nutritional deficiencies, how your body composition will shift. These are precisely the questions that the research has largely failed to answer.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFourth, the trial populations may not reflect your reality.\u003c\/strong\u003e With diabetes prevalence in many trials exceeding 70% — far higher than in real-world practice — patients without diabetes may wonder how applicable the results are to them. Similarly, with a median of 69.8% female participants, the evidence is somewhat skewed toward what works in women, though the researchers note these populations are comparable to those generally reported in the bariatric surgery literature.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations\u003c\/h2\u003e\n\n\u003cp\u003eThe researchers acknowledge several limitations to their own study:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRCTs only:\u003c\/strong\u003e The review focused exclusively on randomized controlled trials. This provides a \"fragmented view\" of the scientific literature, since other study types — particularly cohort studies and database analyses — can provide valuable complementary evidence on long-term outcomes such as life expectancy and rare complications.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMethodological reasoning:\u003c\/strong\u003e The choice to focus on RCTs was deliberate, because evidence from RCTs sits at the top of the \"evidence pyramid\" — the hierarchy of study designs based on their ability to establish cause and effect. Clinical practice decisions, the researchers note, are ideally based on well-conducted RCTs. But this means some important evidence from other study designs falls outside their analysis.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for the Future\u003c\/h2\u003e\n\n\u003cp\u003eThe study offers a clear roadmap for improving bariatric surgery research. While these recommendations are aimed primarily at researchers and policymakers, they matter for patients too — because better research translates into better care.\u003c\/p\u003e\n\n\u003ch3\u003eDevelop a Core Outcome Set (COS)\u003c\/h3\u003e\n\n\u003cp\u003eThe researchers strongly recommend creating a standardized \u003cstrong\u003ecore outcome set (COS)\u003c\/strong\u003e — a minimum list of outcomes that every bariatric surgery trial should measure and report. This would help ensure that studies can be compared, combined, and understood, and that important outcomes (quality of life, mental health, nutritional status) are never overlooked.\u003c\/p\u003e\n\n\u003cp\u003eThey emphasize that this COS should be developed with input from a variety of professionals — surgeons, nutritionists, dietitians, psychiatrists, and psychologists — and, crucially, from \u003cstrong\u003epatients who have themselves undergone bariatric surgery\u003c\/strong\u003e. They also recommend that the COS be international in scope and regularly updated.\u003c\/p\u003e\n\n\u003ch3\u003eForm Research Consortia\u003c\/h3\u003e\n\n\u003cp\u003eThe creation of research consortia — collaborative networks of multiple centers and countries working together — is proposed as a key solution. Consortia could improve the coverage of research questions and enable larger, more definitive trials. Currently, the field is characterized by small, national, single-center trials, with only 15% multicenter and 3.5% international.\u003c\/p\u003e\n\n\u003ch3\u003ePrioritize Long-Term Follow-Up\u003c\/h3\u003e\n\n\u003cp\u003eGiven that obesity is a chronic, lifelong disease, the researchers stress the importance of evaluating long-term impacts. Yet less than a quarter of trials followed patients beyond 4 years. They acknowledge that funding long-term studies is a major obstacle, but suggest that researchers should consider other study designs — such as cohort studies and national database analyses — to evaluate long-term effects like life expectancy.\u003c\/p\u003e\n\n\u003ch3\u003eReconsider Research Questions\u003c\/h3\u003e\n\n\u003cp\u003eFuture studies should \"reconsider the questions posed,\" focusing on areas that remain unaddressed rather than repeating existing work. The researchers specifically highlight hypertension resolution, body composition changes, nutritional deficiency risk, and mental health as under-investigated areas that deserve urgent attention.\u003c\/p\u003e\n\n\u003ch3\u003eUse New Research Tools\u003c\/h3\u003e\n\n\u003cp\u003eThe study also suggests that new approaches — like \u003cstrong\u003ephenome-wide association scans (PheWAS)\u003c\/strong\u003e, a method that scans the entire range of health outcomes to discover unexpected connections — could allow certain outcomes to emerge \"without prior hypothesis.\" This data-driven approach could uncover effects of bariatric surgery that researchers haven't thought to look for.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eHow many weight-loss surgery clinical trials were reviewed, and over what time period?\u003c\/h3\u003e\n\u003cp\u003eResearchers reviewed 114 high-quality randomized controlled trials in bariatric surgery, covering research from the first trial in 1977 through 2020. They screened more than 53,000 scientific references to identify these trials, which compared different surgical techniques or surgery against non-surgical treatment in adult patients.\u003c\/p\u003e\n\u003ch3\u003eWhy should I be concerned that most weight-loss surgery studies only follow patients for 1 to 2 years?\u003c\/h3\u003e\n\u003cp\u003eObesity is a lifelong chronic disease, so knowing whether surgery’s benefits and risks last is essential. Yet only about 21% of trials followed patients beyond 4 years, and many followed for just 1 or 2 years. This leaves important questions about long-term outcomes, such as life expectancy and late complications, poorly answered.\u003c\/p\u003e\n\u003ch3\u003eWhat weight-loss surgery procedure has been studied the most, and which is most commonly performed now?\u003c\/h3\u003e\n\u003cp\u003eRoux-en-Y gastric bypass (RYGB) was studied in about 74% of trials and has long been considered a standard procedure. However, sleeve gastrectomy (SG) is now the most commonly performed bariatric procedure worldwide, yet it has been far less studied. This gap means evidence for the most common surgery lags behind.\u003c\/p\u003e\n\u003ch3\u003eAre mental health and quality of life after weight-loss surgery well studied?\u003c\/h3\u003e\n\u003cp\u003eNo. Mental health was studied in only 5% of trials, and quality of life in only one-third. Researchers noted that quality of life is likely the most relevant question to patients themselves, yet it remains under-investigated. This means limited evidence on depression, addiction issues, and daily life after surgery.\u003c\/p\u003e\n\u003ch3\u003eWhat does it mean that many weight-loss surgery trials had small numbers of patients?\u003c\/h3\u003e\n\u003cp\u003eThe median number of patients in each trial was just 61. Half of all trials enrolled fewer than 61 people. Such small studies can be less reliable and may miss important differences between procedures. The researchers described repetition of small, short-term studies as a form of research waste.\u003c\/p\u003e\n\u003ch3\u003eI do not have diabetes. Will weight-loss surgery research results apply to me?\u003c\/h3\u003e\n\u003cp\u003eMaybe not directly. About 39.5% of trials were performed specifically in patients with diabetes, and in those, a median of 69.8% of participants had diabetes. This is much higher than diabetes rates in real-world bariatric surgery patients. So results may be skewed toward people with diabetes.\u003c\/p\u003e\n\u003ch3\u003eWhat do researchers recommend to improve future weight-loss surgery research?\u003c\/h3\u003e\n\u003cp\u003eThey recommend creating a standardized core outcome set, with input from patients and professionals, so every trial measures important things like quality of life, mental health, and nutrition. They also suggest forming international research consortia, prioritizing long-term follow-up, and focusing on neglected areas like hypertension resolution and nutritional deficiencies.\u003c\/p\u003e\n\u003ch3\u003eShould I get a second opinion before bariatric surgery given that research mainly covers short-term weight loss and diabetes, not quality of life or mental health?\u003c\/h3\u003e\n\u003cp\u003eMost bariatric surgery trials follow patients for only one to two years, and half enroll fewer than 61 people. They focus heavily on weight loss and diabetes, while mental health is studied in only 5% of trials and quality of life in one-third. The most common procedure today, sleeve gastrectomy, is less studied than gastric bypass. A second opinion can help you weigh these evidence gaps and clarify realistic long-term expectations before deciding. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Paris HEGP Seventy years of bariatric surgery\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Claire Rives-Lange, Nathalie Rassy, Claire Carette, Aurelie Phan, Charles Barsamian, Jeremie Thereaux, David Moszkowicz, Tigran Poghosyan, and Sebastien Czernichow\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e \u003cem\u003eObesity Reviews\u003c\/em\u003e, 2022;23:e13420 (published by Wiley on behalf of the World Obesity Federation)\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.1111\/obr.13420\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFunding:\u003c\/strong\u003e The study was funded by a grant from the Programme Hospitalier de Recherche Clinique — PHRC 2011 (Ministère de la Santé, AOM11194).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eStudy affiliation:\u003c\/strong\u003e Assistance Publique—Hôpitaux de Paris (AP-HP), Nutrition Department, European Hospital Georges Pompidou, Paris, France; University of Paris; INSERM; and other French institutions.\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eNote: This patient-friendly article is based on peer-reviewed research. It has been written to make the findings accessible to a general audience while preserving all key data, statistics, and conclusions from the original scientific publication. Some authors of the original study disclosed consulting fees and other financial relationships with pharmaceutical and medical device companies; these are detailed in the original article's conflict of interest statement.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47471118712988,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/fr\/products\/70-years-of-weight-loss-surgery-research-what-we-know-what-we-dont-and-why-that-matters-for-patients","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}